Dr. Neil Iyengar & Dr. Mark Robson – PARP Inhibitors in Early Breast Cancer: Who and When to Treat

Playlist - Dr. Neil Iyengar & Dr. Mark Robson

Expanding Germline Testing: Who Should Be Tested for PARP Eligibility?

1 min read

Germline Testing in the Community: Practical Pathways Without Genetics Teams

1 min read

Adjuvant PARP Inhibition: Risk Stratification and Sequencing in High-Risk Patients

1 min read

Beyond BRCA: Emerging Germline Targets for PARP Inhibitors

1 min read

Hormone Receptor Status & BRCA: Does Subtype Matter for PARP Use?

1 min read

PARP vs. CDK4/6 Inhibitors: Which Comes First in HR+ BRCA+ Disease?

1 min read

Long-Term Safety of PARP Inhibitors: Myeloid Risk and Preventive Considerations

1 min read

Managing PARP Inhibitor Toxicity: Practical Tips for Clinicians

1 min read

The Future of Adjuvant PARP Therapy: MRD, ADCs, and Beyond

1 min read